After weight loss, people with overweight and obesity express more of the protein Kallistatin* in subcutaneous white adipose tissue.
AbbVie’s Elahere wins European approval for certain ovarian cancers – Pharmaceutical Technology
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: Skorzewiak via Shutterstock. The European Commission (EC)